Indomethacin pulsincap formulation and it’s in vitro evaluation for colon targeting

Author(s): P.Muthuprasanna, M.Gopinath, K.Suriaprabha, C.Roosewelt, Sridharinaganthi, K.Reetavijayarani, A.Satish Babu

Rheumatoid arthritis (RA) is traditionally considered as a chronic, inflammatory autoimmune disorder that causes the immune system to attack the joints. The symptoms of rheumatoid arthritis are severe in early morning hours, so an attempt has been made to overcome the problem by delaying drug release by colon targeting to maintain peak plasma concentrations in early morning hours[1]. Indomethacin, a non-steroidal anti- inflammatory drug effectively used for treatment of inflammation and pain caused by rheumatoid arthritis, was selected as a model drug[2]. Indomethacin has a plasma half life of 4.5hr. Its administration rate is frequent due to its short half life. The aimof this studywas to develop a pulsincap containingmicro encapsulated Indomethacin (microsponges) to relieve pain and inflammation caused by rheumatoid arthritis in early morning hours which are targeted to colon and also to reduce the gastric irritation.

Share this       

Share this Page.

Table of Contents